Last reviewed · How we verify

Regranex — Competitive Intelligence Brief

Regranex (Regranex) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Platelet-derived growth factor receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Regranex (Regranex) — Solsys Medical LLC.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Regranex TARGET Regranex Solsys Medical LLC marketed Platelet-derived growth factor receptor
Ayvakit AVAPRITINIB Blueprint Medicines marketed Kinase Inhibitor [EPC] Platelet-derived growth factor receptor alpha 2020-01-01
Lartruvo OLARATUMAB Eli Lilly marketed Platelet-derived Growth Factor Receptor alpha Antagonist Platelet-derived growth factor receptor alpha 2016-01-01
Regranex BECAPLERMIN Omj Pharmaceuticals marketed Human Platelet-derived Growth Factor Platelet-derived growth factor receptor 1997-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Regranex — Competitive Intelligence Brief. https://druglandscape.com/ci/regranex. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: